Hans Van Roos joined several members of the CFPC team at the Rotary Breakfast on February 13th. Hans is an avid hiker and one of the leaders of the Chilliwack Outdoors Club. He has also been very helpful and supportive to several of the CFPC members over the years in his capacity as salesman for Vedder Mountain Field Supplies.
All of this is made more poignant by the fact that Hans is currently undergoing treatment for prostate cancer. His courage as he battles the disease was made evident by his willingness to come to the breakfast and offer some advice to the audience. We will be thinking particularly of Hans as we climb Mt. Aconcagua.

Thank You Leisure Chilliwack- Training Begins!

The CFPC team has started core training in preparation for the Climb.

I would like to extend a special thank you on behalf of the team to the Chilliwack leisure center for their on-going support.

We appreciate your top notch facility to include the pool, trainers and weight rooms.

THANK YOU LaureLee

Dr Cox Visit Chilliwack Rotary Breakfast

Associate Professor, Department of Urologic Sciences, University of British Columbia
Senior Scientist, The Vancouver Prostate Centre, Vancouver Coastal health Research Institute

B.Sc. Zoology, Auburn University, AL 1982
M.Sc. Zoology, Auburn University, AL 1985
Ph.D. Biochemistry, University of North Carolina, NC 1991
PDF. Microbiology, University of Virginia, VA


Prostate cancer is the most frequently diagnosed malignancy and the third leading cause of cancer-related deaths in men. The cause of this disease is unknown. Dr. Michael Cox is a molecular and cellular biologist who earned his Ph.D. in Biochemistry from the University of North Carolina who began his work in prostate cancer at the University of Virginia. His research program is dedicated to understanding how prostate cancer initiates and progresses and to finding ways of halting advanced disease progression. Dr. Cox’s research is funded by the Terry Fox Foundation, National Cancer Institute of Canada, the Vancouver Coastal Health Authority Hospital Foundation and the British Columbia Foundation for Prostate Disease. His work focuses on early genetic changes in prostate cells, how resulting tumor cells respond to growth factors in the presence or absence of testosterone and these cellular changes allow prostate tumor cells to utilize these growth factors to aid development of testosterone independence. With colleagues at the University of British Columbia, he is developing antisense and small molecule drug strategies that decrease the responsiveness of tumor cells to growth factors and has shown that prostate cancer cells treated in this way are more sensitive to testosterone deprivation or treatment with other chemotherapies; first steps in developing effective treatments for patients with advanced prostate cancer.